Contract Researchers have taken it on the chin following Parexel's (PRXL) lackluster quarterly results. But that view might be short sighted given drug makers are increasingly turning to CROs to usher drugs through trials.
Shares of Affymetrix have been on fire over the past year despite lacking any real fundamental fuel. Will this hot stock keep rising, or is it destined to crash and burn?
An unexpected court ruling crushes Sequenom. Is this bad news or the buying opportunity investors have been waiting for?
Diagnostics have been taking off around health care, from fast risers like Illumina to tried-and-true companies like Thermo-Fisher. Don't miss out on this health boom.
Which health-care stocks knocked the ball out of the park this week? These three companies scored double-digit gains.
An EU approval for an HIV therapy enhancing drug, mixed late-stage reviews for another big pharmaceutical company, and a rough week for two biotech standouts are this week's top stories.
How about a 50% gain in one week? That's the worst performance among these health-care high flyers.
The details behind Roche's deal with Pacific Biosciences of California.
Is Pacific Biosciences' new arrangement with Roche a good deal? Mr. Market gives PacBio's deal a big thumbs up.
Covance is doing well with its contract research business.